![]() Headache is infrequently reported with lubiprostone, occurring in 2% to 11% of patients at the 24 mcg twice daily dose. In the open-label, long-term studies (6 to 12 months), patients were allowed to reduce the dose of lubiprostone to 24 mcg once daily if experiencing nausea. Of note, the incidence of nausea was substantially lower among men (7%) and elderly patients (18%) when compared to the overall rate. Administering lubiprostone with food decreases the incidence of reported nausea. Among patients receiving 24 mcg twice daily, 1 to 4% reported severe nausea and 2 to 9% discontinued treatment due to nausea. One of the most common adverse reactions associated with lubiprostone is nausea, with a reported incidence of 8% in patients taking 8 mcg twice daily for IBS-C, 17% of patients taking 24 mcg/day for chronic idiopathic constipation, and 11% and 29% of patients taking 24 mcg twice daily for chronic idiopathic constipation and opioid-induced constipation (OIC), respectively. Administration with food minimizes the symptoms of drug-induced nausea. Additionally, long-term, open-label data suggest a sustained response over a 6 to 12 month treatment period.įor storage information, see the specific product information within the How Supplied section. Signs and symptoms related to constipation, including abdominal bloating, abdominal discomfort, stool consistency, and straining, as well as constipation severity ratings, were also improved in the lubiprostone group. In clinical evaluation, statistically significant differences in the timing of the first spontaneous bowel movement (SMB) following initiation of treatment were observed in lubiprostone-treated patients compared to placebo-treated patients approximately 60% of patients experienced an SMB within 24 hours of the first lubiprostone dose compared to roughly 35% in placebo groups. Overall, lubiprostone is well tolerated in all adult populations, including in elderly patients. Furthermore, other agents which effect gastrointestinal motility or inhibit visceral sensitivity (e.g., tegaserod), have not been adequately studied in the elderly suffering from chronic constipation. In comparison, fluid and electrolyte problems, as well as product dependency, have been associated with other products for constipation, such as selected laxatives. Clinically, lubiprostone alters stool consistency and promotes regular bowel movements, without altering serum electrolyte concentrations or producing tolerance, using this unique mechanism. ![]() Guidelines strongly recommend lubiprostone to treat global IBS-C symptoms. Lubiprostone is used to treat adults with chronic idiopathic constipation or opiate agonist-induced constipation (OIC), and is also used in adult women with constipation-predominant irritable bowel syndrome (IBS-C). Chemically, the drug is a bicyclic fatty acid, prostaglandin E1 (PGE 1) derivative that increases intestinal fluid secretion by activating specific ClC-2 chloride channels in the luminal cells of the intestinal epithelium. Lubiprostone is a unique gastrointestinal agent for the treatment of constipation.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |